SAFARI44
Live / Allowed — Published for opposition (as of 10 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 29 Aug 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99365495
- Mark type
- Design + words
- Filed
- 29 Aug 2025
- Published for opposition
- 10 Feb 2026
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes
- Class 042 — Scientific and technological services: Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology
Owner
- Avidity Biosciences, Inc., San Diego, CA, US
- Avidity Biosciences, Inc., San Diego, CA, US
Prosecution history
- 05 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 05 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 05 Mar 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 05 Mar 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 10 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Feb 2026 — PUBLISHED FOR OPPOSITION
- 04 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Jan 2026 — ASSIGNED TO EXAMINER
- 29 Dec 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 29 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 05 Sept 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 05 Sept 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 05 Sept 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED